AUSTIN: The U.S. Food and Drug Administration has granted approval for only five drugs to treat the symptoms of Alzheimer’s disease.
Broomfield-based Accera Inc. wants to develop the sixth and this week named a new CEO to lead the charge.
Dr. Charles Stacey, a former surgeon and neuroscience researcher, has been named president and CEO of the privately held firm. Stacey joined the company in February on an interim basis, coming from Inventages, a life sciences-focused venture capital firm that joined companies including Nestlé in investing in Accera.
Stacey’s appointment headlines a shift in management and strategy for Accera…